D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Adjuvant N-methyl-D-aspartic acid (NMDA)-enhancing agents, such as GlyT-1 inhibitors and
NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia
patients. The purpose of this study is to evaluate efficacy and safety of add-on treatment of
an inhibitor of D-amino acid oxidase (DAAOI), DAAOI-1, in chronically stable schizophrenia
patients who have been stabilized with antipsychotics.